Bristol Myers Squibb and RayzeBio announced a definitive merger agreement under which Bristol Myers Squibb will acquire RayzeBio.
Bristol Myers Squibb and RayzeBio announced a definitive merger agreement under which Bristol Myers Squibb will acquire RayzeBio for $62.50 per share in cash, for a total equity value of approximately $4.1 billion, or $3.6 billion net of estimated cash…